{"raw_mentions": "Here are the extracted sentences:\n\nIt was shown that oseltamivir phosphate had an IC50 of 1.175 \u03bcM compared to an IC50 of 1015 \u03bcM for oseltamivir carboxylate [4].\nLive BMA macrophage cells were pre-treated with clopidogrel bisulfate at 280 \u03bcM and 500 \u03bcM for 2 min followed with 5 \u03bcg/mL of endotoxin lipopolysaccharide (LPS) in the presence or absence of 400 \u03bcM pure oseltamivir phosphate.\nOther studies using recombinant soluble human sialidases have shown that oseltamivir carboxylate scarcely inhibited the activities of the four human sialidases even at 1 mM [8], while zanamivir significantly inhibited the human Neu2 and Neu3 sialidases in the micromolar range.\nFurthermore, Nan et al. using lysates from mature dendritic cells have found that zanamivir completely inhibited Neu1 and Neu3 sialidase activity at 2 mM [9].\nIn addition, other purified neuraminidase inhibitors such as BCX-1827, DANA (2-deoxy-2,3-dehydro-N-acetylneuraminic acid), zanamivir (4-guanidino-Neu5Ac2en), and oseltamivir carboxylate had a limited effect on inhibition of lypopolysaccharide (LPS) induced sialidase activity in live BMC-2 macrophage cells at 1-2 mM compared to the LPS positive control."}
{"final_json": [{"molecule_name": "oseltamivir phosphate", "protein_target_name": null, "binding_metric": "IC50", "value": "1.175", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "oseltamivir carboxylate", "protein_target_name": null, "binding_metric": "IC50", "value": "1015", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "clopidogrel bisulfate", "protein_target_name": null, "binding_metric": null, "value": "280", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "clopidogrel bisulfate", "protein_target_name": null, "binding_metric": null, "value": "500", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "oseltamivir phosphate", "protein_target_name": null, "binding_metric": null, "value": "400", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "oseltamivir carboxylate", "protein_target_name": "human sialidases", "binding_metric": "IC50", "value": "1", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "zanamivir", "protein_target_name": "human Neu2 and Neu3 sialidases", "binding_metric": "IC50", "value": null, "unit": "micromolar range", "is_logarithmic": false}, {"molecule_name": "zanamivir", "protein_target_name": "Neu1 and Neu3 sialidase", "binding_metric": "IC50", "value": "2", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "BCX-1827", "protein_target_name": "sialidase", "binding_metric": null, "value": "1-2", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "DANA (2-deoxy-2,3-dehydro-N-acetylneuraminic acid)", "protein_target_name": "sialidase", "binding_metric": null, "value": "1-2", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "zanamivir (4-guanidino-Neu5Ac2en)", "protein_target_name": "sialidase", "binding_metric": null, "value": "1-2", "unit": "mM", "is_logarithmic": false}, {"molecule_name": "oseltamivir carboxylate", "protein_target_name": "sialidase", "binding_metric": null, "value": "1-2", "unit": "mM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe combination of gemcitabine with oseltamivir phosphate at 5 mg/kg reduced the liver metastases by 81% compared to the untreated control cohort and further reduced the liver metastases by 10% over the monotherapy of the chemotherapeutic drug at day 109 post implantation.\n79untreated00420.2-1.290022638%0.2-1.390052150%0.8-0.278abraxane0.502248%0.2-1.078abraxane0.521955%0.2-0.790abraxane0.552150%0.1-1.0101gemcitabine3001271%0.3-1.5110gemcitabine3021076%0.5-1.2109gemcitabine305881%0.2-1.5\nTable 14 includes IC50 data for the inhibition of Neu1 sialidase by analogues of the antiviral agent 2-deoxy-2,3-dehydro-N-acetyneuraminic acid (DANA). \n2.04 mM 4-MUNANA substrate [2\u2032-(4-methylumbelliferyl)-\u03b1-D-N-acetylneuraminic acid] (Sigma-Aldrich) in Tris buffered saline pH 7.4 was added to each slide alone (control), with predetermined dose of specific ligand, or in combination of ligand and inhibitor at various doses"}
{"final_json": [{"molecule_name": "gemcitabine", "protein_target_name": null, "binding_metric": null, "value": "81%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "oseltamivir phosphate", "protein_target_name": null, "binding_metric": null, "value": "10%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "abraxane", "protein_target_name": null, "binding_metric": null, "value": "0.502248%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "abraxane", "protein_target_name": null, "binding_metric": null, "value": "0.521955%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "abraxane", "protein_target_name": null, "binding_metric": null, "value": "0.552150%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "gemcitabine", "protein_target_name": null, "binding_metric": null, "value": "1271%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "gemcitabine", "protein_target_name": null, "binding_metric": null, "value": "21076%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "gemcitabine", "protein_target_name": null, "binding_metric": null, "value": "5881%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "2-deoxy-2,3-dehydro-N-acetyneuraminic acid (DANA)", "protein_target_name": "Neu1 sialidase", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "4-MUNANA", "protein_target_name": null, "binding_metric": null, "value": "2.04", "unit": "mM", "is_logarithmic": false}]}
